Researchers reported blocking the GPNMB protein responsible for spreading toxic immune cells in neural tissues.
The report adds that targeting GPNMB reduced immune-mediated neural damage in study models.
Scientists said the approach requires further human trials before therapeutic application.
Researchers blocked the GPNMB protein implicated in spreading toxic immune cells in Parkinson’s brain tissue. Spokespersons referred inquiries to previously issued statements.
According to available records, the clinical trial mapped inflammatory pathways that accelerate neurodegenerative progression.
Named entities in source reporting include GPNMB, Parkinson’s researchers.
Available filings identify the parties and venues involved without additional unsourced claims.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/health_medicine/parkinsons-protein-block-19